(Q37442540)

20 August 2017

Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma (English)

1 reference

20 August 2017

hepatocellular carcinoma

1 reference

inferred from title

author name string

Elizabeth A Kuczynski

series ordinal

1

1 reference

PMC publication ID

5124233

20 August 2017

Robert S Kerbel

series ordinal

2

1 reference

20 August 2017

25 November 2016

1 reference

Chinese Journal of Cancer

20 August 2017

1 reference

20 August 2017

35

1 reference

20 August 2017

1

1 reference

20 August 2017

97

1 reference

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

20 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124233

Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124233

Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124233

The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124233

Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124233

Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124233

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124233

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124233

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124233

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124233

Sorafenib in advanced hepatocellular carcinoma

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124233

Epithelial--mesenchymal and mesenchymal--epithelial transitions in carcinoma progression.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124233

Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124233

The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124233

Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124233

Endothelial transdifferentiation in hepatocellular carcinoma: loss of Stabilin-2 expression in peri-tumourous liver correlates with increased survival.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124233

Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5124233

Histologic growth pattern of hepatocellular carcinoma: relationship to orcein (hepatitis B surface antigen)-positive cells in cancer tissue

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27887628

12 December 2020

inferred from PubMed ID database lookup

Immunohistochemical studies on endothelial cell phenotype in hepatocellular carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27887628

12 December 2020

inferred from PubMed ID database lookup

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27887628

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1186/S40880-016-0162-7

0 references

Dimensions Publication ID

0 references

1 reference

PMC publication ID

5124233

20 August 2017

PubMed publication ID

27887628

1 reference

PMC publication ID

5124233